186 related articles for article (PubMed ID: 35852473)
1. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
Xiang ZZ; He T; Zeng YY; Liu F; Shao BF; Yang T; Ma JC; Wang XR; Yu ST; Liu L
Cancer Med; 2023 Jan; 12(2):1102-1113. PubMed ID: 35852473
[TBL] [Abstract][Full Text] [Related]
2. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.
Yang H; Liu Y; Zhang R; Ye Y; Chen Q; Qin Q; Huang L; Li X; Cai R; Tang H; Jiang W
Oral Oncol; 2020 Nov; 110():104897. PubMed ID: 32679404
[TBL] [Abstract][Full Text] [Related]
5. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
8. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
9. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
10. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
He SS; Wang Y; Bao Y; Cai XY; Yang XL; Chen DM; Chen Y; Lu LX
Cancer Med; 2018 Apr; 7(4):1110-1117. PubMed ID: 29493874
[TBL] [Abstract][Full Text] [Related]
13. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
14. Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Zheng H; Zhou P; Wang J; Yu YF; Zhou R; Lin Q; Wu SG
Cancer Med; 2023 Jul; 12(14):14979-14987. PubMed ID: 37212447
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
[TBL] [Abstract][Full Text] [Related]
16. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
18. MRI-Based Deep-Learning Model for Distant Metastasis-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang L; Wu X; Liu J; Zhang B; Mo X; Chen Q; Fang J; Wang F; Li M; Chen Z; Liu S; Chen L; You J; Jin Z; Tang B; Dong D; Zhang S
J Magn Reson Imaging; 2021 Jan; 53(1):167-178. PubMed ID: 32776391
[TBL] [Abstract][Full Text] [Related]
19. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
20. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
Zong J; Ji P; Lin C; Zhang R; Chen Y; Lu Q; Peng X; Pan J; Lin S
Oral Oncol; 2022 Aug; 131():105972. PubMed ID: 35728415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
